Quadrivalent HPV (Types 6, 11, 16, 18) Recombinant Vaccine

For information about cervical cancer, please visit the Cervical Cancer website.
GARDASIL is indicated in females aged 9 through 45 years for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18 (which are included in the vaccine). 

GARDASIL is also indicated in males 9 through 26 years of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by HPV Types 6, 11, 16, and 18.
This product is available only with a doctor’s prescription.

Who is this information for?
This information is relevant in Australia and is intended for people who have been prescribed this product or health care professionals.

Consumer Medicine Information
The Consumer Medicine Information (CMI) is a leaflet written for consumers. The CMI contains information about the medicine including:
  • What this product is used for
  • How it works
  • Before and after the vaccination
  • How this product is given
  • Side effects
GARDASIL Consumer Medicine Information (PDF, 222KB)

Product Information
Product Information contains information to ensure the safe and effective use of a medicine. This document is approved by the Therapeutic Goods Administration and made available by bioCSL for you if you are a:
  1. qualified healthcare professional; or
  2. consumer, provided you have read the Consumer Medicine Information for the product; want further information on the product; and agree to consult with your healthcare professional if you have any questions in relation to the Product Information.
Gardasil Product Information (PDF, 551KB)

Gardasil® is a Registered Trademark of Merck & Co. Inc.

Last Updated: 29/09/2013
© 2016 CSL Limited